This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Arch Intern Med. 1994;154(15):1665-1672.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

THE MANAGEMENT of hypertension results in more visits by adults to physicians than any other disease; effective treatment over the past 20 years has significantly reduced progression from less severe to more severe hypertension and has been a major factor in the reduction of fatal strokes by 57% and coronary heart disease (CHD) deaths by more than 45%.¹ Cost considerations have begun to play an important role in treatment decisions.² As newer technologies and medications add to the cost of care, it is important to consider whether or not limiting cost will affect the quality of care or outcome in managing this disease.

Hypertension costs can be controlled by the following: (1) by limiting the complexities of the initial evaluation, avoiding the temptation to employ technologies that have not been shown to improve outcome, and (2) by selecting therapy based on studies over the past 20 years, and . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?